GLP-1受体激动剂对胃肠道的影响:机制,管理和未来方向
Ryan J Jalleh1, Chris K Rayner1, Trygve Hausken2
1Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, SA, Australia.
The lancet. Gastroenterology & hepatology
|August 3, 2024
概括
葡萄糖类-1 (GLP-1) 受体激活剂显著影响胃排空,可能在手术前增加吸入风险. 需要进一步的研究,以为服用这些药物的患者制定明确的手术前指导方针.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 代谢性疾病管理管理
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激动剂 (RAs) 正在改变2型糖尿病和肥胖症治疗.
- 众所周知,这些药物,包括liraglutide,semaglutide和tirzepatide,都会影响胃排空.
研究的目的:
- 审查GLP-1和GLP-1RA对胃肠道生理学的影响,重点关注胃排空.
- 讨论对手术前和手术前指导方针的影响.
- 解决目前对长效GLP-1RA缺乏证据的问题,并提出管理途径.
主要方法:
- 文献综述和关于GLP-1 RA对胃空化的影响的当前知识的综合.
- 分析延迟胃空气对临床实践的影响,特别是在医疗程序之前.
- 开发建议的程序前管理策略.
主要成果:
- 短期和长期起作用的GLP-1RA显然会延迟胃排空.
- 虽然有利于血糖控制,但显著的延迟可能会增加食物吸收等风险.
- 对长效GLP-1RA对胃空化的影响的证据基础对于目前的指导方针制定是不够的.
结论:
- 为了程序安全性,GLP-1 RA疗法需要仔细考虑胃排空.
- 由于证据有限,目前的程序前指南是不充分的,特别是对于长效药物.
- 进一步的研究对于为GLP-1RA患者提供基于证据的管理途径至关重要.
相关概念视频
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: Glinides
150
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
150
Oral Hypoglycemic Agents: Biguanides and Glitazones
185
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
185
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
233
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
233


